Johnson & Johnson's Innovation Hub is on a dealmaking spree, announcing 17 collaborations across a variety of therapeutic spaces and geographic regions – fostering a new set of deals that the big pharma is watching for partnership down the line.
J&J dips its fingers in new tech and diseases
More from Alimentary/Metabolic
More from Therapy Areas
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
• By
JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.
• By
CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.